Publications by authors named "Gert Ossenkoppele"

Claim this Profile
D
Different features of acute myeloid leukemia stem cell quantification in intensively treated patients.
Lok Lam Ngai, Tom Reuvekamp, Diana Hanekamp, Fleur Janssen, Laura Oudshoorn-van Marsbergen, Gert J Ossenkoppele

Haematologica· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.
Lukas H Haaksma, Raffaele Palmieri, Tom Reuvekamp, Jesse M Tettero, Lok Lam Ngai, Gert J Ossenkoppele

Leukemia· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2025 Update on MRD in Acute Myeloid Leukemia: A Consensus Document from the ELN-DAVID MRD Working Party.
Jacqueline Cloos, Peter J M Valk, Christian Thiede, Konstanze Döhner, Gail J Roboz, Gert J Ossenkoppele

Blood· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
Tim R Mocking, Lukas H Haaksma, Tom Reuvekamp, Angèle Kelder, Willemijn J Scholten, Gert J Ossenkoppele

Leukemia· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The added value of Bayesian interim analysis in randomized phase II and phase III clinical trials in hemato-oncology.
Anna J T Smit, Niek G Van der Maas, Bronno Van der Holt, Yvette Van Norden, Erik Van Werkhoven, Gert J Ossenkoppele

Haematologica· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A revised prognostic model for patients with acute myeloid leukemia and first relapse.
Niek G van der Maas, Dimitri Breems, Clara P W Klerk, Thomas Pabst, Patrycja Gradowska, Gert Ossenkoppele

Blood Adv· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surface downmodulation of TIM3 safeguards healthy cells but not acute myeloid leukemia from CAR T-cell therapy.
Jort J van der Schans, Paresh Vishwasrao, Renée Poels, Morgan Antti, Ziyu Wang, Gert J Ossenkoppele

Hemasphere· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance.
Marta Anna Sobas, Amin T Turki, Angela Villaverde Ramiro, Alberto Hernández-Sánchez, Javier Martinez Elicegui, Gert Ossenkoppele

Haematologica· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Adriano Venditti, Raffaele Palmieri, Luca Maurillo, Christoph Röllig, Agnieszka Wierzbowska, Gert Ossenkoppele

Blood Adv· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients.
Sjoerd J F Hermans, Jurjen Versluis, Erik D van Werkhoven, Yvette van Norden, Jeroen J W M Janssen, Gert J Ossenkoppele

Br J Haematol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
Tom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, Jannemieke Carbaat-Ham, Mona M H E Fayed, Gert J Ossenkoppele

Leukemia· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML.
Christian M Vonk, Tim Grob, Melissa Rijken, François G Kavelaars, Jolinda M L Konijnenburg, Gert J Ossenkoppele

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.
Dietger Niederwieser, Dirk Hasenclever, Wolfgang E Berdel, Bart J Biemond, Haifa Al-Ali, Gert Ossenkoppele

Haematologica· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.
Tom Reuvekamp, Luca L G Janssen, Lok Lam Ngai, Jannemieke Carbaat-Ham, Daphne den Hartog, Gert J Ossenkoppele

Cytometry B Clin Cytom· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome.
Gerwin Huls, Dana A Chitu, Lidwine Tick, Rinske Boersma, Dimitri Breems, Gert J Ossenkoppele

Ann Hematol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Acute promyelocytic leukemia: long-term outcomes from the HARMONY project.
Maria Teresa Voso, Luca Guarnera, Söhren Lehmann, Konstanze Döhner, Hartmut Döhner, Gert Ossenkoppele

Blood· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk Stratification in Older Intensively Treated Patients With AML.
Jurjen Versluis, Marlen Metzner, Ariel Wang, Patrycja Gradowska, Abin Thomas, Gert J Ossenkoppele

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations.
Hartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, Charles Craddock, Hervé Dombret, Gert Ossenkoppele

Blood· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML).
Eduardo Rodríguez-Arbolí, Megan Othus, Sylvie D Freeman, Francesco Buccisano, Lok Lam Ngai, Gert J Ossenkoppele

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of AMG 330 in adults with relapsed/refractory AML: a phase 1a dose-escalation study.
Farhad Ravandi, Marion Subklewe, Roland B Walter, Pankit Vachhani, Gert Ossenkoppele

Leuk Lymphoma· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications - a HARMONY study.
Alberto Hernández-Sánchez, Teresa González, Marta Sobas, Eric Sträng, Gastone Castellani, Gert Ossenkoppele

Leukemia· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission.
Francois-Xavier Mahon, Markus Pfirrmann, Stéphanie Dulucq, Andreas Hochhaus, Panayiotis Panayiotidis, Gert Ossenkoppele

J Clin Oncol· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of hemodilution on flow cytometry based measurable residual disease assessment in acute myeloid leukemia.
Jesse M Tettero, Maaike E Heidinga, Tim R Mocking, Glenn Fransen, Angèle Kelder, Gert J Ossenkoppele

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial.
Niek G van der Maas, Jurjen Versluis, Kazem Nasserinejad, Joost van Rosmalen, Thomas Pabst, Gert J Ossenkoppele

Blood Cancer J· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis